9/26
07:09 am
oriny
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer [Yahoo! Finance]
Neutral
Report
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer [Yahoo! Finance]
9/26
04:00 am
oriny
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
Neutral
Report
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
9/25
08:00 am
oriny
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
Neutral
Report
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
9/20
02:37 am
oriny
213,285 Orion Corporation A shares converted into B shares [Yahoo! Finance]
Neutral
Report
213,285 Orion Corporation A shares converted into B shares [Yahoo! Finance]
9/11
02:35 am
oriny
Inside information: Orion upgrades full-year outlook for 2024 [Yahoo! Finance]
Neutral
Report
Inside information: Orion upgrades full-year outlook for 2024 [Yahoo! Finance]
9/2
02:03 pm
oriny
3 Reasons Why Growth Investors Shouldn't Overlook Orion OYJ (ORINY) [Yahoo! Finance]
Neutral
Report
3 Reasons Why Growth Investors Shouldn't Overlook Orion OYJ (ORINY) [Yahoo! Finance]
8/22
03:36 am
oriny
Orion Corporation: Managers' transactions – Satu Ahomäki [Yahoo! Finance]
Neutral
Report
Orion Corporation: Managers' transactions – Satu Ahomäki [Yahoo! Finance]
8/20
09:29 am
oriny
Orion Corporation: Managers' transactions – Liisa Hurme [Yahoo! Finance]
Medium
Report
Orion Corporation: Managers' transactions – Liisa Hurme [Yahoo! Finance]
8/16
01:38 am
oriny
Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement [Yahoo! Finance]
Low
Report
Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement [Yahoo! Finance]